Suppr超能文献

人乳头瘤病毒基因型的特征及其在向埃塞俄比亚妇女提供的疫苗中的覆盖率。

Characterization of human papillomavirus genotypes and their coverage in vaccine delivered to Ethiopian women.

机构信息

Department of Health Biotechnology, Institute of Biotechnology, Bahir Dar University, P. O. Box 79, Bahir Dar, Ethiopia.

Amhara Public Health Institute, Bahir Dar, Ethiopia.

出版信息

Sci Rep. 2024 Apr 4;14(1):7976. doi: 10.1038/s41598-024-57085-z.

Abstract

Cervical cancer is a significant public health concern in Ethiopia. It is mainly caused by persistent infection with the human papillomaviruses. The aim of this study was to assess the relationship between carcinogenic risk of probable, possible and low risk HPV infection and those of cervical intraepithelial neoplasia (CIN) and cervical cancer. A cross sectional study nested from prospective cohort study was conducted in Bahir Dar, northwest Ethiopia. Statistical analyses were performed using SPSSversion 26.0. HPV-16 was associated with a relatively higher risk of CIN II, (AOR = 15.42; 95% CI 6.81-34.91). In addition, HPV-52, -18, -53 and -58, were significantly associated with an increased risk of CIN II, (AOR = 7.38 (1.73-31.54), 5.42 (1.61-18.31), 4.08 (1.53-10.87), and 3.17 (1.00-10.03)), respectively. The current study shows high rate of HPV with predominance of HPV-16, -53, -58, -18, -35, and -52. The quadrivalent and nonavalent vaccine had only covered 27.1% and 45% of the circulating HPV genotypes. Ethiopia may need to consider introduction of nonavalent vaccine into the national public health strategy. Polyvalent vaccine which includes the genotypes not covered by existing approved vaccines should be considered.

摘要

宫颈癌是埃塞俄比亚一个重大的公共卫生问题。它主要是由人乳头瘤病毒的持续感染引起的。本研究旨在评估可能的、可能的和低风险 HPV 感染与宫颈上皮内瘤变(CIN)和宫颈癌之间的致癌风险关系。本研究采用病例对照研究嵌套的横断面研究方法,在埃塞俄比亚西北部的巴希尔达尔进行。统计分析使用 SPSSversion 26.0 进行。HPV-16 与 CIN II 的相对较高风险相关(AOR=15.42;95%CI 6.81-34.91)。此外,HPV-52、-18、-53 和 -58 与 CIN II 的风险增加显著相关(AOR=7.38(1.73-31.54)、5.42(1.61-18.31)、4.08(1.53-10.87)和 3.17(1.00-10.03))。本研究显示 HPV 感染率较高,以 HPV-16、-53、-58、-18、-35 和 -52 为主。目前的疫苗仅涵盖了循环 HPV 基因型的 27.1%和 45%。埃塞俄比亚可能需要考虑将九价疫苗纳入国家公共卫生战略。应考虑使用包含现有批准疫苗未涵盖基因型的多价疫苗。

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验